eligibility_summary
Eligible: adults ≥18 with advanced/unresectable/metastatic HER2‑expressing solid tumors, ECOG 0–1, measurable disease, adequate organ/marrow function, FFPE sample for HER2, contraception/consent, women postmenopausal or pregnancy‑test negative. Exclude: breast or gastric/GEJ adenocarcinoma, effusions requiring drainage, CNS mets/LM, unresolved toxicities, serious infection (TB/HIV/HBV/HCV), ILD, cardiac dysfunction, recent chemo/surgery, allergy, other trial, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, open-label trial (DESTINY-PanTumor03) of trastuzumab deruxtecan (T-DXd, DS-8201a) monotherapy or with bevacizumab in advanced HER2-expressing solid tumors (excluding breast/gastric). T-DXd is an antibody–drug conjugate: trastuzumab (anti-HER2 mAb) linked via cleavable linker to a topoisomerase I inhibitor (DXd). It binds HER2, is internalized, releases DXd to induce DNA damage/apoptosis, has a bystander effect, and can inhibit HER2 signaling/mediate ADCC. Bevacizumab is an anti-VEGF-A monoclonal antibody that blocks angiogenesis. Targets/pathways: HER2/ERBB2 on tumor cells, topoisomerase I/DNA replication, and VEGF/VEGFR signaling in tumor endothelium.